Journal: The Clinical Biochemist Reviews

Article Title: Proceedings of the Australasian Association of Clinical Biochemists’ 56 th Annual Scientific Conference

doi:

Figure Lengend Snippet: ME Craig

Article Snippet: EQA results were comparable with peers participating in the College of American Pathologist and DEQAS proficiency testing.

Techniques: Mass Spectrometry, Biomarker Discovery, Diagnostic Assay, Histopathology, Imaging, Flow Cytometry, Suspension, Coagulation, Methylation, Nuclear Magnetic Resonance, Structural Proteomics, Control, Binding Assay, Activity Assay, Laser Capture Microdissection, Comparison, Liquid Chromatography, Extraction, Marker, Quantitation Assay, Clinical Proteomics, Inter Assay, Dissolution, Chromatography, Hydrophilic Interaction Liquid Chromatography, Centrifugation, Immunofluorescence, Mutagenesis, Software, High Throughput Screening Assay

Journal: Journal of Diabetes Science and Technology

Article Title: Evaluation of Performance of Laboratories and Manufacturers Within the Framework of the IFCC model for Quality Targets of HbA1c

doi: 10.1177/1932296817741320

Figure Lengend Snippet: IFCC model applied to 128 individual laboratories in SKML 2017-3 EQA program in the Netherlands. The mean within-laboratory CV is on the horizontal axis; the laboratory absolute bias is on the vertical axis (IFCC in mmol/mol; NGSP in %). The circles (laboratory instruments) and squares (POCT instruments) represent the performance of individual laboratories with colors for analytical principles: green (immunoassays), red (ion exchange HPLC), yellow (boronate affinity), blue (capillary electrophoresis), pink (Enzymatic assays). For details see text.

Article Snippet: As an example shows the results of a recent EQA program of the foundation for quality assurance in medical laboratories (SKML, Stichting Kwaliteits Bewaking Medische Laboratoria) in the Netherlands.

Techniques: Electrophoresis

Journal: Journal of Medical Biochemistry

Article Title: Six SIGMA evaluation of 17 biochemistry parameters using bias calculated from internal quality control and external quality assurance data

doi: 10.5937/jomb0-43052

Figure Lengend Snippet: Average CV (%) values of level 1 and 2 IQC samples, bias (%) values calculated from IQC and EQA samples, and TEa values obtained from CLIA'88 for 17 biochemistry parameters.

Article Snippet: Bias (%) = [(our IQC or EQA result – Beckman Coulter IQC mean, or peer group mean of EQA)/Beckman Coulter IQC mean, or peer group mean of EQA] x100 Total allowable error (TEa) values were decided according to Clinical Laboratory Improvement Amendments Specifications (CLIA’88).

Techniques:

Journal: Journal of Medical Biochemistry

Article Title: Six SIGMA evaluation of 17 biochemistry parameters using bias calculated from internal quality control and external quality assurance data

doi: 10.5937/jomb0-43052

Figure Lengend Snippet: Quality control procedures selected for parameters.

Article Snippet: Bias (%) = [(our IQC or EQA result – Beckman Coulter IQC mean, or peer group mean of EQA)/Beckman Coulter IQC mean, or peer group mean of EQA] x100 Total allowable error (TEa) values were decided according to Clinical Laboratory Improvement Amendments Specifications (CLIA’88).

Techniques:

Journal: EJIFCC

Article Title: Evaluation of the Correlation Coefficient of Polyethylene Glycol Treated and Direct Prolactin Results and Comparability with Different Assay System Results

doi:

Figure Lengend Snippet: Correlation of EQAS results of Cycle 13

Article Snippet: The z-scores of EQAS results (Immunoassay, BIORAD, Cycle 13) showed no outlying score in the complete cycle but remarkable discrepancy was observed with the peer mean of other immunoassay systems.

Techniques:

Journal: EJIFCC

Article Title: Evaluation of the Correlation Coefficient of Polyethylene Glycol Treated and Direct Prolactin Results and Comparability with Different Assay System Results

doi:

Figure Lengend Snippet: Reverse correlation of EQAS results Cycle 13

Article Snippet: The z-scores of EQAS results (Immunoassay, BIORAD, Cycle 13) showed no outlying score in the complete cycle but remarkable discrepancy was observed with the peer mean of other immunoassay systems.

Techniques: